Aromasin (Exemestane) - Published Studies

Aromasin Related Published Studies

Well-designed clinical trials related to Aromasin (Exemestane)

Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. [2012]

Exemestane for breast-cancer prevention in postmenopausal women. [2011.06.23]

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. [2011.06.10]

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. [2011.04.20]

A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. [2011.04]

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. [2011.01.22]

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy. [2010.12]

Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. [2010.11]

Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. [2010.05]

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. [2010.03]

A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. [2010.01]

Bioequivalence of exemestane in post-menopausal females. [2010]

Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy. [2010]

Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. [2010]

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. [2010]

Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. [2009.09]

Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. [2009.08]

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. [2009.07]

The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. [2009.06]

A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. [2009.02]

Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. [2009]

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. [2008.10.20]

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. [2008.04.20]

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. [2008.04.01]

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat.Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. [2008.03.10]

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: Results From EFECT. [2008.03.03]

Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. [2007.11]

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. [2007.10.20]

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. [2007.05]

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. [2007.02.17]

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. [2006.11]

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. [2006.10.11]

Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials. [2006.02]

The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. [2005.09]

Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. [2005.09]

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. [2005.08.01]

A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. [2005.03]

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. [2004.03.11]

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. [2004.02]

Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. [2003.12]

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. [2003.09]

Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate. [2003.07]

[Treatment of advanced metastatic breast cancer with exemestane, a multicenter randomized controlled study of 195 cases] [2003.02.10]

[Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer] [2002.07]

[Phase I multiple-dose administration study of exemestane in postmenopausal women] [2002.07]

Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. [2001.02.01]

Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. [2000.09]

Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. [2000.09]

Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial. [2000.09]

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. [2000.04]

The minimal effective exemestane dose for endocrine activity in advanced breast cancer. [1997.04]

Well-designed clinical trials possibly related to Aromasin (Exemestane)

Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial. [2011.05]

Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole. [2011.02]

[Assessment of the quality of life of women with breast cancer in adjuvant treatment with tamoxifen or aromatase inhibitors--a randomized trial]. [2011.01]

Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention. [2010.12.15]

Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole. [2010.09.28]

Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. [2010.03.01]

Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy. [2009.07]

Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. [2008.12]

Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. [2008.08]

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. [2008.05]

Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. [2008.04]

Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials. [2008.01]

Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. [2007.12.28]

Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials. [2007.10.16]

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. [2007.07.15]

The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. [2007.06]

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. [2007.05.30]

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. [2007]

What is the optimal strategy for postoperative treatment with aromatase inhibitors in the adjuvant setting? [2006.12]

Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. [2006.02.01]

Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. [2005.11]

Serum lipid profiles in patients receiving endocrine treatment for breast cancer--the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial. [2005.10]

The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. [2004.10.01]

Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. [2004]

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. [2003.09]

The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention. [2001.12]

Other research related to Aromasin (Exemestane)

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. [2012]

Exemestane for breast cancer prevention: a critical shift? [2012]

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. [2012]

Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. [2012]

Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). [2012]

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study. [2011.11.21]

Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. [2011.08.18]

The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. [2011.08]

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. [2011.06.29]

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. [2011.06]

Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. [2011.05]

Drug safety evaluation of exemestane. [2011.05]

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. [2011]

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. [2011]

A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. [2011]

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. [2011]

[A successful case of the super elderly breast cancer patient treated with exemestane]. [2010.11]

Alternative oral exemestane formulation: Improved dissolution and permeation. [2010.10.15]

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy. [2010.09.08]

Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. [2010.08.21]

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. [2010.07.01]

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy. [2010]

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. [2010]

A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. [2010]